Spray-dried mRNA vaccine powder stays potent in the fridge for 3 years
The biggest logistical headache in mRNA medicine isn't the science—it's the freezer.
A new delivery format sidesteps ultra-cold storage entirely, and it's just one of several ideas this week quietly rewriting what mRNA can do.
🧊 No Freezer Required: mRNA Vaccines That Last 3 Years in the Fridge
- The researchers tested whether an experimental dry vaccine formulation retained activity during refrigerated storage.
- The powder held its potency—colloidal stability, mRNA integrity, and biological activity—for over 3 years under refrigerated conditions. Liquid formulations showed substantial degradation within 6–9 months under the same conditions.
- The investigators compared the stored product with a liquid formulation in preclinical tests.
Why it matters: A vaccine that can use existing refrigerators could be easier to distribute. Clinical studies would need to establish its performance in people.
Key Findings
🤖 AI Picks Better Lipid Nanoparticles—Then Proves It in Mice
- Starting from a 520-compound library, researchers trained a machine learning model on cell-based transfection data, then used it to virtually screen 10,920 candidate lipids. The top pick, PA97MD101, delivered mRNA to mouse livers more effectively than standard formulations and successfully silenced a disease-relevant gene via CRISPR.
- The researchers compared their predictions with experimental measurements, including results from mice.
❤️ mRNA Prompts Mouse Hearts to Regenerate After a Heart Attack
- A modified mRNA encoding two proteins—Myc and cyclin T1—triggered adult cardiomyocytes to divide and replace lost tissue after myocardial infarction in mice. Adult mammalian hearts normally lack this capacity entirely.
- Critically, the effect required only transient expression. Sustained activation caused problems; the brief mRNA pulse was enough to drive repair and functional recovery.
🫁 Lung-Targeting Nanoparticles Cut Fibrosis Scarring by ~40% in Mice
- Researchers evaluated an experimental mRNA treatment for lung fibrosis in mice.
- Treated mice showed approximately 40% less collagen deposition by histology and significantly reduced hydroxyproline content—a direct marker of fibrotic scarring.
💉 New Moderna Vaccine Outperforms Pfizer's in Older Veterans
- A comparative effectiveness study in older US veterans during the 2025–2026 respiratory season found that mRNA-1283, Moderna's newer vaccine targeting immunodominant spike regions, provided higher estimated protection against severe COVID-19 than BNT162b2.
- This is the first real-world effectiveness data for mRNA-1283 in an older adult population, a group that remains at elevated risk for severe outcomes.
🦟 One mRNA Vaccine Targets Both Zika and Dengue—Without the Backfire Risk
- A bispecific mRNA vaccine combined a Zika neutralizing antibody module with conserved T-cell epitopes from both Zika and dengue. The design deliberately separated the antibody-generating and T-cell-generating components to avoid antibody-dependent enhancement—the phenomenon where cross-reactive antibodies can worsen dengue infection.
- In immunodeficient mice, the vaccine protected against challenge from both viruses and produced neutralizing antibody titers up to 8-fold higher than an unadjuvanted comparison.
🧫 mRNA Converts Stem Cells to Blood Vessel Cells at 97% Efficiency
- Ionizable lipid nanoparticles delivered mRNA encoding a single transcription factor to human pluripotent stem cells, converting more than 97% of cells and generating endothelial cell populations with average purities above 90%—without any genome integration.
- The approach worked across a wide range of cell densities and mRNA doses, suggesting the process is robust enough to scale for tissue engineering or cell therapy manufacturing.
Implications
mRNA platforms are converging on the same unsolved problem from multiple angles: getting the right molecule to the right cell outside the liver, at the right time, without triggering the immune system on repeat doses. The powder stability and lung-targeting results narrow the delivery gap—but whether any of these formats can reach non-liver tissues reliably in humans remains the open question.
Studies in this issue
Primary sources used for this newsletter.
- Spray-Dried mRNA Nanoparticle Powder for Multiple Delivery Methods with 3-Year Stability in the Fridgemain storyAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026-11-10PMID 43006795
- Turning human stem cells into blood vessel cells using ETV2 mRNA delivered by special lipid nanoparticleskey findingActa biomaterialia2026-11-13PMID 43025678
- Effectiveness of mRNA-1283 compared to BNT162b2 COVID-19 vaccines in older US veteranskey findingJAMA network open2026-11-11PMID 43013304
- Temporary mRNA carrying Myc and cyclin T1 improves heart function after injurykey findingNature cardiovascular research2026-11-09PMID 43003910
- mRNA vaccine targeting Zika and dengue viruses to prevent harmful immune reactions and protect in early animal testskey findingEmerging microbes & infections2026-11-10PMID 43007258
- Using AI to find biodegradable lipids that improve liver delivery of mRNA in living organismskey findingNature communications2026-11-09PMID 43003859
- Lipid nanoparticles that target lungs deliver SMAD7 mRNA to reduce lung scarringkey findingJournal of controlled release : official journal of the Controlled Release Society2026-11-10PMID 43009023
Continue reading
All mRNA Technology issuesGet the next mRNA Technology issue
Seven papers, once a week. Free.